Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells

Front Immunol. 2024 May 14:15:1382911. doi: 10.3389/fimmu.2024.1382911. eCollection 2024.

Abstract

Introduction: COVID-19 vaccines are highly effective in inducing protective immunity. While the serum antibody response to COVID-19 vaccination has been studied in depth, our knowledge of the underlying plasmablast and memory B cell (Bmem) responses is still incomplete. Here, we determined the antibody and B cell response to COVID-19 vaccination in a naïve population and contrasted it with the response to a single influenza vaccination in a primed cohort. In addition, we analyzed the antibody and B cell responses against the four endemic human coronaviruses (HCoVs).

Methods: Measurement of specific plasma IgG antibodies was combined with functional analyses of antibody-secreting plasmablasts and Bmems. SARS-CoV-2- and HCoV-specific IgG antibodies were quantified with an in-house bead-based multiplexed immunoassay.

Results: The antibody and B cell responses to COVID-19 vaccination reflected the kinetics of a prime-boost immunization, characterized by a slow and moderate primary response and a faster and stronger secondary response. In contrast, the influenza vaccinees possessed robust immune memory for the vaccine antigens prior to vaccination, and the recall vaccination moderately boosted antibody production and Bmem responses. Antibody levels and Bmem responses waned several months after the 2nd COVID-19 vaccination, but were restored upon the 3rd vaccination. The COVID-19 vaccine-induced antibodies mainly targeted novel, non-cross-reactive S1 epitopes of the viral spike protein, while cross-reactive S2 epitopes were less immunogenic. Booster vaccination not only strongly enhanced neutralizing antibodies against an original SARS-CoV-2 strain, but also induced neutralizing antibodies against the Omicron BA.2 variant. We observed a 100% plasma antibody prevalence against the S1 subunits of HCoVs, which was not affected by vaccination.

Discussion: Overall, by complementing classical serology with a functional evaluation of plasmablasts and memory B cells we provide new insights into the specificity of COVID-19 vaccine-induced antibody and B cell responses.

Keywords: COVID-19 vaccination; HCoV; cross-reactive antibodies; dynamics; influenza; memory B cell; original antigenic sin; plasmablast.

MeSH terms

  • Adult
  • Antibodies, Neutralizing / blood
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral* / blood
  • Antibodies, Viral* / immunology
  • B-Lymphocytes / immunology
  • COVID-19 Vaccines* / immunology
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • Cross Reactions* / immunology
  • Epitopes, B-Lymphocyte / immunology
  • Female
  • Humans
  • Immunity, Humoral*
  • Immunoglobulin G* / blood
  • Immunoglobulin G* / immunology
  • Immunologic Memory / immunology
  • Influenza Vaccines / immunology
  • Kinetics
  • Male
  • Memory B Cells* / immunology
  • Middle Aged
  • Plasma Cells* / immunology
  • SARS-CoV-2* / immunology
  • Spike Glycoprotein, Coronavirus / immunology
  • Vaccination

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Immunoglobulin G
  • Influenza Vaccines
  • Antibodies, Neutralizing
  • Epitopes, B-Lymphocyte
  • Spike Glycoprotein, Coronavirus

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was funded by grants to BB from the Federal State of Mecklenburg-Western Pomerania (“COVIDPROTECT”, grant no. GW-20-0004) and to SH from the Research Network Molecular Medicine (FVMM) of the University Medicine Greifswald (grant no. FOVB-2021-01). HF, MV, and RR were supported by the federal state Schleswig-Holstein, Germany and by the Medical Faculty of the University of Kiel (grant no. ÖGD5-109353/2020).